Pharma Mar
€70.75Change from previous close: −3.21%Absolute change: −€2.35
At a glance
- Revenue growth
- +26.61%
- 2025 vs 2024
- Net income growth
- +187.03%
- 2025 vs 2024
- Net margin
- 33.9%
- 2024: 14.9%
Financial data
Amounts in millions of EUR; per-share values in EUR; shares in millions.
| Item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Total revenue | 221 | 175 | 158 | 196 |
| Cost of revenue | 12.3 | 8.2 | 9.6 | 13.6 |
| Gross profit | 209 | 167 | 149 | 183 |
| Selling, general and administrative | -2.1 | -2.7 | -4.3 | 43.2 |
| Research and development | 95.2 | 104 | 99.3 | 83.4 |
| Operating income | 60.0 | 6.0 | -3.9 | 44.4 |
| EBIT | 62.1 | 14.5 | -1.2 | 46.2 |
| EBITDA | 70.1 | 21.2 | 4.5 | 52.1 |
| Interest expense | 2.5 | 2.5 | 2.4 | 2.4 |
| Pre-tax income | 59.7 | 12.0 | -3.6 | 43.8 |
| Income tax | -15.3 | -14.1 | -4.8 | -5.6 |
| Net income | 75.0 | 26.1 | 1.1 | 49.4 |
| Net income to common shareholders | 75.0 | 26.1 | 1.1 | 49.4 |
| Basic EPS | 4.30 | 1.49 | 0.06 | 2.73 |
| Diluted EPS | 4.30 | 1.49 | 0.06 | 2.73 |
| Average shares (basic) | 17.4 | 17.5 | 17.9 | 18.1 |
| Average shares (diluted) | 17.5 | 17.6 | 17.9 | 18.1 |